Shaya, Justin
Kato, Shumei
Adashek, Jacob J. http://orcid.org/0000-0003-4272-312X
Patel, Hitendra
Fanta, Paul T.
Botta, Gregory P.
Sicklick, Jason K.
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA023100, P30 CA023100, P30 CA023100, P30 CA023100, P30 CA023100)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 22 August 2022
Accepted: 7 December 2022
First Online: 20 January 2023
Competing interests
: S.K. serves as a consultant for Foundation Medicine. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. J.J.A. serves on the advisory board of CureMatch, Inc. G.P.B. serves on the Advisory Board of Natera and as a consultant to TumorGen Inc. and CEND Therapeutics. H.P. worked as consultant/scientific advisory board member for Epinoma. S.K. serves as a consultant for Foundation Medicine. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. J.K.S. receives research funding from Amgen Pharmaceuticals and Foundation Medicine, consultant fees from Deciphera, speaker’s fees from Deciphera, Foundation Medicine, La-Hoffman Roche, Merck, MJH Life Sciences, and QED Therapeutics. R.K. received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Daiichi Sankyo, Inc., EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc., CureMetrix, and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. The remaining authors declare no competing interests.